IP-cure-B clinical trial
Do you know that there is a clinical trial going on in the framework of the IP-cure-B project?
TheANRS HB07 clinical trial issponsored by ANRS | Emerging Infectious Diseasesand takes place in different centres across Europe involved in the project.
The objective of the EU-funded IP-cure-B project is to develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine. Researchers will also identify immune and viral biomarkers for monitoring patient stratification and treatment response. Integrating biological and clinical data will enable models for the best combination of treatment and effectiveness of novel curative therapies concerning disease spectrum and patient heterogeneity. The preclinical platform will be evaluated in humanised mice, combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses. Proof of concept will be obtained in a clinical trial of a combination of novel compounds stimulating innate immunity.
Outcomes for medical experts
The project aims at proposing a treatment paradigm shift with the development of novel combination therapies for CHB with improved cure rates and a better appraisal of novel biomarkers to improve patient selection for treatment and monitoring treatment response.
Outcomes for community
The development of such curative therapies with a finite duration of administration will pave the way towards a universal treatment of all individuals that suffer from chronic HBV infection. It is thus expected to result in a long-term reduction in cost and global burden of CHB (short-term therapy, increased treatment uptake in the infected population, decreased rate of liver complications and mortality).
Outcomes for patient
The project aims at designing and developing novel treatment strategies towards the cure of infection with a shorter duration of treatment. It is expected to result in improved quality of life and decreased social stigma.
|LIST OF CLINICAL TRIAL SITES|
|HOSPITAL||HEAD OF DEPARTMENT||PRINCIPAL INVESTIGATOR||ADDRESS|
|Hospices Civils de Lyon (France)||Pr. Fabien ZOULIM|
|Pr. Fabien ZOULIM|
Telephone (secretary) : 04 26 10 93 55
Carrie Newsom, Study coordinator
103 Grande Rue de la Croix-Rousse
|UniversitatKlinikum in Freiburg (Germany)||Pr. Robert THIMME|
|Pr. Robert THIMME|
|Department of Internal Medicine|
Clinic for Internal Medicine II – Gastroenterology,
Hepatology, Endocrinology and Infectiology
Hugstetter Street 55
|Hôpital Saint-Joseph (France)||Pr. Marc BOURLIERE|
|Pr. Marc BOURLIERE|
26 boulevard de Louvain
13285 Marseille Cedex 8
|Fondazione IRCCS Ca’ GrandaOspedale Maggiore Policlinico in Milan (Italy)||Pr. Pietro LAMPERTICO|
|Pr. Pietro LAMPERTICO|
|Gastroenterology and Hepatology Division|
Via Francesco Sforza 35
|University Hospital of Parma (Italy)||Pr. Ovidio BUSSOLAFI|
|Pr. Carlo FERRARI|
|Department of General and Specialized Medical AreaAziendaOspedalieraUniversitaria di Parma Via Gramsci 14|
|Hôpital Pitié Salpêtrière (France)||Pr. Dominique THABUT|
|Pr. Vlad RATZIU|
|Service towpath-gastroentérologie Hôpital Pitié Salpêtrière 47-83, boulevard de l’hôpital 75651 Paris cedex 13|
CHU Hôtel-Dieu, Nantes (France)
|Dr Jérôme GOURNAY|
|Dr Jérôme GOURNAY|
|CHU Hôtel-Dieu Service d’hépato-gastro-entérologie|
Institut des Maladies de l’Appareil Digestif 1 place Alexis Ricordeau 44093 Nantes Cedex 01
Vall d’Hebron University Hospital in Barcelona (Spain)
|Pr. Maria BUTI|
|Pr. Maria BUTI|
|Internal Medicine and Hepatology|
Passeig de la Vall d’Hebron, 119
ELPA: [email protected]
ANRS | Emerging infectious Diseases: [email protected]